ARCUTIS BIOTHERAPEUTICS ($ARQT) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$0.09 per share, missing estimates of -$0.08 by $0.01. The company also reported revenue of $105,400,000, beating estimates of $103,286,220 by $2,113,780.
Stock price change since market close: -2.9%
You can see Quiver Quantitative's $ARQT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARCUTIS BIOTHERAPEUTICS Insider Trading Activity
ARCUTIS BIOTHERAPEUTICS insiders have traded $ARQT stock on the open market 43 times in the past 6 months. Of those trades, 0 have been purchases and 43 have been sales.
Here’s a breakdown of recent trading of $ARQT stock by insiders over the last 6 months:
- TODD WATANABE (See Remarks) has made 0 purchases and 5 sales selling 107,182 shares for an estimated $2,963,642.
- PATRICK BURNETT (See Remarks) has made 0 purchases and 10 sales selling 56,557 shares for an estimated $1,468,139.
- MASARU MATSUDA (See Remarks) has made 0 purchases and 11 sales selling 56,903 shares for an estimated $1,463,395.
- HOWARD G. WELGUS has made 0 purchases and 5 sales selling 47,144 shares for an estimated $1,245,242.
- KEITH R LEONARD sold 39,272 shares for an estimated $997,194
- NEHA KRISHNAMOHAN has made 0 purchases and 2 sales selling 40,504 shares for an estimated $939,493.
- LARRY TODD EDWARDS (See Remarks) has made 0 purchases and 4 sales selling 34,870 shares for an estimated $878,096.
- SUE-JEAN LIN sold 25,272 shares for an estimated $777,955
- HALLEY E GILBERT sold 16,532 shares for an estimated $455,441
- LATHA VAIRAVAN (SVP Chief Financial Officer) has made 0 purchases and 3 sales selling 4,173 shares for an estimated $105,501.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ARCUTIS BIOTHERAPEUTICS Hedge Fund Activity
We have seen 164 institutional investors add shares of ARCUTIS BIOTHERAPEUTICS stock to their portfolio, and 108 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 5,496,113 shares (-44.9%) from their portfolio in Q4 2025, for an estimated $159,607,121
- RUBRIC CAPITAL MANAGEMENT LP removed 2,477,880 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $71,957,635
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,486,000 shares (+14.2%) to their portfolio in Q4 2025, for an estimated $43,153,440
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,465,441 shares (+133.6%) to their portfolio in Q4 2025, for an estimated $42,556,406
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,078,546 shares (+1228.4%) to their portfolio in Q4 2025, for an estimated $31,320,975
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 900,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,136,000
- STATE STREET CORP added 846,986 shares (+18.2%) to their portfolio in Q4 2025, for an estimated $24,596,473
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ARCUTIS BIOTHERAPEUTICS Congressional Stock Trading
Members of Congress have traded $ARQT stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ARQT stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 12/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
ARCUTIS BIOTHERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ARQT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 11/28/2025
To track analyst ratings and price targets for ARCUTIS BIOTHERAPEUTICS, check out Quiver Quantitative's $ARQT forecast page.
ARCUTIS BIOTHERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ARQT recently. We have seen 5 analysts offer price targets for $ARQT in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Uy Ear from Mizuho set a target price of $35.0 on 03/02/2026
- Seamus Fernandez from Guggenheim set a target price of $35.0 on 02/27/2026
- Serge Belanger from Needham set a target price of $36.0 on 02/26/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $34.0 on 02/26/2026
- Tyler Van Buren from TD Cowen set a target price of $35.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
